1887
Preview this article:
Zoom in
Zoomout

On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of type B 16S toxin-haemagglutinin, Page 1 of 1

| /docserver/preview/fulltext/micro/152/7/1891a-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.28862-0
2006-07-01
2020-04-10
Loading full text...

Full text loading...

/deliver/fulltext/micro/152/7/1891a.html?itemId=/content/journal/micro/10.1099/mic.0.28862-0&mimeType=html&fmt=ahah

References

  1. Aoki K. R. 2002; Immunologic and other properties of therapeutic botulinum toxin serotypes. In Scientific and Therapeutic Aspects of Botulinum Toxin pp 103–113 Edited by Brin M. F., Hallett M., Jankovic J.. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
  2. Arimitsu H, Inoue K, Sakaguchi Y, Lee J, Fujinaga Y, Watanabe T, Ohyama T, Hirst R, Oguma K. 2003; Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia. Infect Immun71:1599–1603[CrossRef]
    [Google Scholar]
  3. Atassi M. Z. 1977; Chemical modification and cleavage of proteins and chemical strategy in immunochemical studies of proteins. In Immunochemistry of Proteinsvol. 1 pp 1–161 Edited by Atassi M. Z.. New York: Plenum;
    [Google Scholar]
  4. Atassi M. Z. 1984; Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur J Biochem145:1–20[CrossRef]
    [Google Scholar]
  5. Atassi M. Z. 2002; Immune recognition and cross-reactivity of botulinum neurotoxins. In Scientific and Therapeutic Aspects of Botulinum Toxins pp 385–408 Edited by Brin M. F., Hallett M., Jankovic J.. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
  6. Atassi M. Z. 2004; Basic immunological aspects of botulinum toxin therapy. Mov DisordSuppl 8:S68–S84
    [Google Scholar]
  7. Atassi M. Z, Oshima M. 1999; Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol19:219–260
    [Google Scholar]
  8. Atassi M. Z, Dolimbek B. Z, Hayakari M, Middlebrook J. L, Whitney B, Oshima M. 1996; Mapping of the antibody-binding regions on botulinum neurotoxin H-Chain domain 855–1296 with anti-toxin antibodies from three host species. J Protein Chem15:691–700[CrossRef]
    [Google Scholar]
  9. Atassi M. Z, Dolimbek G. S, Deitiker P. R, Aoki K. R, Dolimbek B. Z. 2005; Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol Immunol42:1509–1520[CrossRef]
    [Google Scholar]
  10. Borodic G. E, Acquadro M, Johnson E. A. 2001; Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs10:1531–1544[CrossRef]
    [Google Scholar]
  11. Brashear A, Lew M. F, Dykstra D. D.10 other authors 1999; Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology53:1439–1446[CrossRef]
    [Google Scholar]
  12. Brashear A, McAfee A. L, Kuhn E. R, Fyffe J. 2004; Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil85:705–709[CrossRef]
    [Google Scholar]
  13. Callaway J. E, Arezzo J. C, Grethlein A. J. 2002; Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Dis Mon48:367–383[CrossRef]
    [Google Scholar]
  14. Chen J, Fitos I, Hage D. S. 2006; Chromatographic analysis of allosteric effects between ibuprofen and benzodiazepines on human serum albumin. Chirality18:24–36[CrossRef]
    [Google Scholar]
  15. Coyle E. M, Blazer L. L, White A. A, Hess J. L, Boyle M. D. 2006; Practical applications of high-affinity, albumin-binding proteins from a group G streptococcal isolate. Appl Microbiol Biotechnol71:39–45[CrossRef]
    [Google Scholar]
  16. Dolimbek G. S, Dolimbek B. Z, Aoki K. R, Atassi M. Z. 2005; Mapping of the antibody and T cell recognition profiles of the H[sub]N[/sub] domain (residues 449–859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest34:119–142
    [Google Scholar]
  17. Dressler D, Bigalke H. 2005; Botulinum toxin type B de novo therapy of cervical dystonia frequency of antibody induced therapy failure. J Neurol252:904–907[CrossRef]
    [Google Scholar]
  18. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. 1997; Botulinum A toxin therapy: neutralizing and nonneutralizing Abs – therapeutic consequences. Exp Neurol147:96–102[CrossRef]
    [Google Scholar]
  19. Inagi K, Ford C. N, Rodriquez A. A, Schultz E, Bless D. M, Heisey D. M. 1997; Efficacy of repeated botulinum toxin injections as a function of timing. Ann Otol Rhinol Laryngol106:1012–1019[CrossRef]
    [Google Scholar]
  20. Jankovic J. 2002; Botulinum toxin clinical implications of antigenicity and immunoresistance. In Scientific and Therapeutic Aspects of Botulinum Toxin pp 409–415 Edited by Brin M. F., Hallett M., Jankovic J.. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
  21. Jankovic J. 2004; Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatr75:951–957[CrossRef]
    [Google Scholar]
  22. Jankovic J, Hunter C, Atassi M. Z, Dolimbek B. Z, Dolimbek G. S. BOS Research Group 2005; Botulinum toxin type B observational study (BOS). Mov Disord20:S31
    [Google Scholar]
  23. Jemmerson R, Margoliash E. 1978; In Immunobiology of Proteins and Peptidesvol. 1 pp 119–129 Edited by Atassi M. Z., Stavitsky A. B.. New York: Plenum;
    [Google Scholar]
  24. Jemmerson R, Margoliash E. 1979; Topographic antigenic determinants on cytochrome c . Immunoadsorbent separation of the rabbit antibody populations directed against horse cytochrome. J Biol Chem254:12706–12716
    [Google Scholar]
  25. Komatsu T, Ohmichi N, Nakagawa A, Zunszain P. A, Curry S, Tsuchida E. 2005; O[sub]2[/sub] and CO binding properties of artificial hemoproteins formed by complexing iron protoporphyrin IX with human serum albumin mutants. J Am Chem Soc127:15933–15942[CrossRef]
    [Google Scholar]
  26. Lee J.-C, Yokota K, Arimitsu H.7 other authors 2005; Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology151:3739–3747[CrossRef]
    [Google Scholar]
  27. Lin H. C, Chen P. C, Cheng T. J, Chen R. L. 2004; Formation of tannin-albumin nano-particles at neutral pH as measured by light scattering techniques. Anal Biochem325:117–120[CrossRef]
    [Google Scholar]
  28. Marini I, Moschini R, Corso A. D, Mura U. 2005; Chaperone-like features of bovine serum albumin: a comparison with alpha-crystallin. Cell Mol Life Sci62:3092–3099[CrossRef]
    [Google Scholar]
  29. Means G. E, Feeney R. E. 1971; Chemical Modification of Proteins San Francisco: Holden-Day;
    [Google Scholar]
  30. Militello V, Casarino C, Emanuele A, Giostra A, Pullara F, Leone M. 2004; Aggregation kinetics of bovine serum albumin studied by FTIR spectroscopy and light scattering. Biophys Chem107:175–187[CrossRef]
    [Google Scholar]
  31. Oliva A, Santovena A, Farina J, Llabres M. 2003; Effect of high shear rate on stability of proteins: kinetic study. J Pharm Biomed Anal33:145–155[CrossRef]
    [Google Scholar]
  32. Poewe W, Deuschl G, Nebe A.8 other authors 1998; What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatr64:13–17[CrossRef]
    [Google Scholar]
  33. Reichlin M, Nisonoff A, Margoliash E. 1970; Immunological activity of cytochrome c . 3. Enhancement of antibody detection and immune response initiation by cytochrome c polymers. J Biol Chem245:947–954
    [Google Scholar]
  34. Rosenberg J. S, Middlebrook J. L, Atassi M. Z. 1997; Localization of the regions on the C-terminal domain of the heavy chain of botulinum toxin A recognized by T-lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest26:491–504[CrossRef]
    [Google Scholar]
  35. Rozak D. A, Orban J, Bryan P. N. 2005; G148-GA3: a streptococcal virulence module with atypical thermodynamics of folding optimally binds human serum albumin at physiological temperatures. Biochim Biophys Acta 1753;226–233[CrossRef]
    [Google Scholar]
  36. Vaiana S. M, Emanuele A, Palma-Vittorelli M. B, Palma M. U. 2004; Irreversible formation of intermediate BSA oligomers requires and induces conformational changes. Proteins55:1053–1062[CrossRef]
    [Google Scholar]
  37. Yablon S. A, Daggett S, Brin M. F. 2005; Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment. In 57th Annual Meeting of the American Academy of Neurology , Abstract P01.153, 12 April 2005 Miami Beach, Florida:
    [Google Scholar]
  38. Young C. R, Atassi M. Z. 1982; Genetic control of the immune response to myoglobin. IX. Overcoming genetic control of antibody response to antigenic sites by increasing the dose of antigen used in immunization. J Immunogen9:343–351[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.28862-0
Loading

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error